AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00398372
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00398372
Drug: Epratuzumab
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02125279
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01953445
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03489005
Drug: Moxifloxacin 400 mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as follows:~- 400 mg moxifloxacin, as 1 × 400-mg tablet
Trial: NCT00195377
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00567840
Drug: PA-824
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg, 600 mg, 100 mg, 1200 mg qd
Trial: NCT00016588
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04211090
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
Trial: NCT04211090
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
Trial: NCT04211090
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
Trial: NCT00802828
Drug: Famotidine Tablets, 40 mg
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01015222
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose of 50 mg daily PO for 28 day cycle
Trial: NCT01015222
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose 5 mg/kg IV Day 1 and 15
Trial: NCT01015222
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose 40 mg/m2 IV Day 1, 8 and 15
Trial: NCT01592045
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:~If weight \> 12 kg: 80 mg/m\^2/dose twice daily (total daily dose is 160 mg/m\^2/day, divided twice daily).~If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily).
Trial: NCT00746317
Drug: GC33
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV administration at 4 escalating dose levels.
Trial: NCT00027391
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00027391
Drug: Oxandrolone
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02513004
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
Trial: NCT03916406
Drug: PF 06835919
RxNorm normalized name: PF-06835919
DrugBank: PF-06835919 (DB19163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg
Trial: NCT03916406
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7.5 mg
Trial: NCT02513004
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
Trial: NCT01028677
Drug: intranasal spray with oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
Trial: NCT03973138
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab (0.5mg Lucentis®; Genentech, South San Francisco, CA) under the pro re nata (PRN) treatment regimen. The retreatment were conducted if BCVA was reduced by 0.1 logarithm of the minimal angle of resolution (logMAR) value or more from maximum acuity or if OCT central subfield thickness was more than 300μm.
Trial: NCT01342029
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.~500-1,000 mg po bid for 2 weeks
Trial: NCT01063855
Drug: Dapoxetine
RxNorm normalized name: dapoxetine
DrugBank: Dapoxetine (DB04884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
Trial: NCT03944655
Drug: Strepsils Anaesthetic Formula
RxNorm normalized name: Strepsils Anaesthetic Formula
DrugBank: Hexylresorcinol (DB11254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of a Strepsils® Max Plus lozenge containing the active ingredients amylmetacresol 0.6 mg, 2,4-dichlorobenzyl alcohol 1.2 mg, lignocaine hydrochloride 10mg with sweeteners and flavourings.
Trial: NCT03365336
Drug: polyherbal formulation
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each Flu Care consist of 350 mg of polyherbal component
Trial: NCT03365336
Drug: Oseltamivir 75mg
RxNorm normalized name: oseltamivir 75 MG
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All the participant has to take 75 mg of oseltamivir for five days.
Trial: NCT00001890
Drug: Estrogen therapy
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04356339
Drug: Interferon-beta-1b (BETASERON, BAY 86-5046)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using the BETACONNECT autoinjector and myBETAapp as prescribed by the physician
Trial: NCT03714022
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive abatacept at a single dose 750 mg as IV infusion.
Trial: NCT02824354
Drug: Nalmefene (Selincro®) 18 mg tablet
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
Trial: NCT01063855
Drug: PDE5I (phosphodiesterase-5 inhibitor)
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
Trial: NCT02646020
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
Trial: NCT02646020
Drug: Desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
Trial: NCT02646020
Drug: Placebo of aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
Trial: NCT02646020
Drug: Placebo of desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
Trial: NCT01018563
Drug: MORAb-003
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
Trial: NCT01048697
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) \> 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)
Trial: NCT00667394
Drug: MLN-518 (Tandutinib)
RxNorm normalized name: MLN-977
DrugBank: MLN-977 (DB05431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandutinib 500 mg by mouth daily dose twice a day.
Trial: NCT02159040
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SC or IV AZA at 75mg/m2 7 days/28 day cycle
Trial: NCT02159040
Drug: Azacitidine plus Deferasirox
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day
Trial: NCT03106454
Drug: Norethindrone
RxNorm normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethindrone 1.05mg
Trial: NCT03952078
Drug: CPI-818
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 inducible T-cell Kinase Inhibitor
Trial: NCT01749098
Drug: PF-04958242
RxNorm normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
Trial: NCT01749098
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
Trial: NCT01749098
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
Trial: NCT02127125
Drug: Maltodextrin
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
Trial: NCT02127125
Drug: Synbiotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic \[5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
Trial: NCT02127125
Drug: Sevelamer
RxNorm normalized name: Sevelamer
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
Trial: NCT04344951
Drug: UNIKINON (Chloroquine phosphate) 200mg tablets
RxNorm normalized name: Chloroquine Phosphate Tablets
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two and a half tablets (500mg) twice daily for seven days.
Trial: NCT02767752
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03109236
Drug: GCSF
RxNorm normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 doses of GCSF injection will be injected under the skin on the abdomen to mobilize the bone marrow cells.
Trial: NCT00153985
Drug: Busulfex
RxNorm normalized name: Busulfex
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given once daily for 4 days
Trial: NCT00153985
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously once daily for 4 days
Trial: NCT00153985
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One day before fludarabine and busulfex are started, alemtuzumab will be given once daily for 5 days.
Trial: NCT02117986
Drug: colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
Trial: NCT03937141
Drug: ADU-S100
RxNorm normalized name: ADU-S100
DrugBank: ADU-S100 (DB14722)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intratumoral
Trial: NCT03400683
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 microgram misoprostol in sublingual every four hours for a maximum of five doses
Trial: NCT03400683
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg( letrozole 2.5mg) on three successive day
Trial: NCT01371825
Drug: Sebelipase alfa (SBC-102)
RxNorm normalized name: SBC-102
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
Trial: NCT02973360
Drug: Docosahexaenoic Acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT02584855
Drug: Ixekizumab
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT03106519
Drug: Liposome bupivacaine + bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00895843
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
Trial: NCT00098527
Drug: romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00589550
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04446091
Drug: Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs and chemotherapy for colorectal mucinous adenocarcinoma
Trial: NCT00990444
Drug: Insulin in Dextran Matrix
RxNorm normalized name: Matrix
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
Trial: NCT02469155
Drug: ITI-007
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02469155
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00129753
Drug: Alemtuzumab (Campath-1H)
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Escalating dose 3mg, 10 mg, 30 mg on three consecutive days, then 30 mg three times per week by subcutaneous injections for 12 weeks. Each 30 mg dose will be divided in 2 injections to be administered in each thigh.
Trial: NCT02521714
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00004077
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004077
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004077
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01424813
Drug: Albuterol MDPI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Trial: NCT00786552
Drug: pemetrexed + paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
Trial: NCT02373579
Drug: Omega-3 Fatty Acids
RxNorm normalized name: Omega-3 Fatty Acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study group, included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day .
Trial: NCT01358331
Drug: MK-8353
RxNorm normalized name: vitamin MK 7
DrugBank: Vitamin K7 (DB15664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally twice daily for 28 days for each cycle
Trial: NCT00563849
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
Trial: NCT01722318
Drug: Plecanatide
RxNorm normalized name: Plecanatide
DrugBank: Plecanatide (DB13170)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00911651
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 µg inhalation once
Trial: NCT00911651
Drug: ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 µg inhalation once
Trial: NCT01293942
Drug: irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
Trial: NCT00368875
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally